IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Eun Jeong PARK, et al.)	Group Art Unit: 1645
Serial No.: 10/088,202)	Examiner: Vanessa L. Ford
Filed: March 15, 2002)	
Title: Novel Detoxified Mutants of Escherichia Coli Heat-Labile Enterotoxin)	

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply dated February 5, 2008, enclosed herewith in full compliance with 37 C.F.R. 1.821-1.825 is a Substitute Sequence Listing to be inserted into the specification. The Substitute Sequence Listing in no way introduces new matter into the specification.

Also submitted herewith in full compliance with 37 C.F.R. §§ 1.821-1.825 is a computer readable form (CRF) copy of the Sequence Listing. Applicant's undersigned representative hereby states that the information recorded in the CRF is identical to the written sequence listing.

Respectfully submitted,

JHK Law

Dated: March 5, 2008

By:/Joseph Hyosuk Kim/ Joseph Hyosuk Kim, Ph.D. Reg. No. 41,425

P.O. Box 1078 La Canãda, CA 91012-1078

Telephone: (818) 952-7430 Facsimile: (818) 952-7424



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/088,202	03/15/2002		Eun Jeong Park	58049-00003	1462
35736 JHK LAW	7590 02	2/05/2008		EXAMINER	
P.O. BOX 10	P.O. BOX 1078			FORD, VANESSA L	
LA CANADA, CA 91012-1078		A 91012-1078	ART UNIT	PAPER NUMBER	
				1645	
				MAIL DATE	DELIVERY MODE
				02/05/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice to Comply

Application No. 10/088,202	Applicant(s) Park et al.	
Examiner	Art Unit	
Vanessa L. Ford	1645	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
 □ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). □ 7. MPEP section 2424 discloses that the sequence listing must include for example <110> must include only the applicant's surnames, the actual inventors. The company name should not be included. Applicant must review the entire application and bring it into compliance with the sequence rules as set for in 37 C.F.R. 1.821-1.825. Applicant Must Provide: □ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
☑ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (571) 272-0731 or (571) 272-0951 For CRE Submission Help, call (571) 272-2510

Patentin Software Program Support

Technical Assistance.1-866-217-9197 or 703-305-3028 or 571-272-6845

PatentIn Software is Available At www.USPTO.gov

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Vanessa L. Ford, Examiner AU 1645 Remsen 3B25, Mailbox 3C18 571-272-0857

NITA MINIFIELD
PRIMARY EXAMINER



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO. /CONTROL NO. 10/088,202	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION Park et al.	ATTORNEY DOCKET NO. 58049-00003
	3/15/2002		

EXAMINER

, Vanessa L. Ford

ART UNIT PAPER

1645

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

The addresses below are effective 5 June 2004. Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

- Electronically submitted through EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual - ePAVE)
- 2. Mailed to:

Mail Stop Sequence

Commissioner for Patents

P.O. Box 22313-1450

Alexandria, VA 22313-1450

3. Hand Carry, Federal Express, United Parcel Service or other delivery service to:

U.S. Patent and Trademark Office

Mail Stop Sequence

Customer Window

Randolph Building

401 Dulaney Street Alexandria, VA 22314

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Vanessa L. Ford whose telephone number is (571) 272-0857.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Shanon Foley at (571-272-0898).

PRIMARY EXAMINER

Sequence Count Sheet		10/088,202	Park et al.	
		Examiner	Art Unit	
		Vanessa L. Ford	1645	
Mark on	ly one space below		DATE OF COUNT	
	(CRFN) (CRF is unreadable; use	CRF Diskette Problem Repo	ort)	
	(CRFD) (CRF does not comply; use Notice to Comply)			
	(CRFR) (CRF required but none submitted; use Notice to Comply)			
	(bona fide) (second or subsequent letter to applicant reporting bona fide attempt to comply; use Notice to Comply and send copy of RSL)			
	(non bona fide) (second or subsequent letter to applicant reporting non-bona fide attempt to comply; use Notice to Comply and send copy of RSL)			

Application/Control No.

Applicant(s)